On December 10, 2015 Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, reported that new data will be presented demonstrating the role of the myChoice HRD companion diagnostic in identifying patients with breast cancer who are likely to respond to a platinum-containing therapy (Press release, Myriad Genetics, DEC 10, 2015, View Source [SID:1234508523]). The data will be presented at the 2015 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"There is mounting clinical evidence demonstrating the ability of myChoice HRD to identify patients who experience improved outcomes when treated with platinum-containing therapy," said Anne-Renee Hartman, M.D., vice president of clinical development, Myriad Genetic Laboratories. "Our collaborators will present data showing how this test might be useful to optimize therapy selection for patients. The data underscore the critical importance of identifying patients at the time of diagnosis who are likely to benefit from a therapeutic response to platinum prior to surgery. These findings support earlier studies showing that myChoice HRD gives the most complete picture of clinical response to platinum-containing chemotherapy."

Details about the featured myChoice HRD presentations at SABCS are below. Follow Myriad on Twitter via @MyriadGenetics and stay informed about symposium news and updates by using the hashtag #SABCS15.

myChoice HRD Presentations

Title: Homologous recombination deficiency (HRD) as a predictive biomarker of response to neoadjuvant platinum-based therapy in patients with triple negative breast cancer (TNBC); A pooled analysis.
Date: Thursday, Dec.10, 2015: 5:00 to 7:00 p.m. CT.
Location: Poster P3-07-12.
Presenter: Dr. Melinda Telli, Stanford University Cancer Center.

A pooled analysis of five Phase II trials that included patients with TNBC treated with neoadjuvant platinum-based chemotherapy was conducted to evaluate the pathologic complete response (pCR) rates in homologous recombination (HR) deficient and HR non-deficient tumors. HR deficiency status was defined as either a positive myChoice HRD score (42 or higher) or presence of a BRCA1/2 tumor mutation (tBRCA). The results of this analysis with 267 patients showed that myChoice HRD predicted pCR in TNBC across several different platinum-based chemotherapy regimens. Specifically, patients with a positive myChoice HRD score had a five-fold increase in pCR compared to those with negative score.

Title: Homologous recombination deficiency (HRD) as a predictive biomarker of response to preoperative systemic therapy (PST) in TBCRC008 comprising a platinum in HER2-negative primary operable breast cancer.
Date: Thursday, Dec.10, 2015: 5:00 to 7:00 p.m. CT.
Location: Poster P3-07-13.
Presenter: Dr. Roisin Connolly, Johns Hopkins School of Medicine.

This study assessed the ability of myChoice HRD to predict pathological complete response (pCR) in 48 patients with ER-positive or triple negative breast cancer who were treated with PST comprising a platinum drug. In the analysis of all patients, the results showed a significantly higher pCR rate in patients with a positive myChoice HRD score than a negative score (50 percent vs 8 percent, p=0.002). A similar trend was observed for both ER-positive and TNBC patients. In a subgroup analysis of patients without a tBRCA mutation (n=40), there was a significantly higher pCR rate in patients with a positive myChoice HRD score than a negative score (64 percent vs 8 percent, p≤0.001). These results show that myChoice HRD predicts response to a platinum-containing chemotherapy regimen in the estimated 15 percent of newly diagnosed breast cancer patients with TNBC. Furthermore, this is the first study to show that myChoice HRD may be useful in predicting response to platinum-containing chemotherapy regimens in patients with ER-positive, Her2-negative breast cancer, which represents approximately 70 percent of newly diagnosed breast cancer patients.

For more information about these presentations, please visit the SABCS website at View Source

About myChoice HRD

Myriad’s myChoice HRD is the first homologous recombination deficiency test that can detect when a tumor has lost the ability to repair double-stranded DNA breaks, resulting in increased susceptibility to DNA-damaging drugs such as platinum drugs or PARP inhibitors. High myChoice HRD scores reflective of DNA repair deficiencies are prevalent in all breast cancer subtypes, ovarian and most other major cancers. In previously published data, Myriad showed that the myChoice HRD test predicted drug response to platinum therapy in certain patients with triple-negative breast and ovarian cancers. It is estimated that 1.8 million people in the United States and Europe who are diagnosed with cancers annually may be candidates for treatment with DNA-damaging agents.